Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RAISN 2: Prospective Randomized Trial of Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care

NCT07699640 is registered in ClinicalTrials.gov with Heinrich-Heine University, Duesseldorf as lead sponsor.

NCT NCT07699640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07699640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RAISN 2: Prospective Randomized Trial of Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care
Lead sponsor
Heinrich-Heine University, Duesseldorf
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
January 31, 2031
Enrollment
171 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

testicular cancer, testicular germ cell tumor